文献速递胸部肿瘤放疗放疗物理与技术

肺癌专家对Ⅰ期非小细胞肺癌治疗意见的多学科调查

Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey.
PubMed 文献 · Adv Radiat Oncol · 2018-01-31

该调查通过28项网络问卷邀请美国放射肿瘤学会、美国胸科学会胸科肿瘤学分会及国际肺癌研究协会的参与提供者,了解其对Ⅰ期非小细胞肺癌治疗证据、临床实践及随机对照试验实施的看法;共完成959份调查,64%为放射肿瘤科医生,49%来自美国以外。大多数放射肿瘤科医生认为立体定向体部放疗与手术获益相同或更好,非放射肿瘤科医生持此观点者较少;几乎全部放射肿瘤科医生和62%非放射肿瘤科医生允许患者入组立体定向体部放疗对比手术的随机对照试验。

要点

  • 80%放射肿瘤科医生认为当前证据显示立体定向体部放疗对可手术Ⅰ期非小细胞肺癌的获益与手术相同或更好,非放射肿瘤科医生仅28%持此观点(P < .01)。
  • 94%放射肿瘤科医生 versus 62%非放射肿瘤科医生允许可手术患者入组立体定向体部放疗对比手术的随机对照试验(P < .01)。
  • 82%放射肿瘤科医生和87%非放射肿瘤科医生认为即使随机对照试验显示立体定向体部放疗生存更好,改变胸外科实践也有些困难、非常困难或不可能(P = .066)。

核心结论

  • 非放射肿瘤科医生认为立体定向体部放疗效果远不如手术,而放射肿瘤科医生认为两者相似。
  • 大多数人支持随机对照试验,但非放射肿瘤科医生支持度较低。
  • 即使随机对照试验显示立体定向体部放疗死亡率和生活质量更好,改变外科实践可能仍有挑战。

研究设计与样本

  • 采用28项网络问卷调查,邀请美国放射肿瘤学会、美国胸科学会胸科肿瘤学分会及国际肺癌研究协会的所有参与提供者分享意见。
  • 共完成959份调查,64%来自放射肿瘤科医生,49%来自美国以外。

主要发现

  • 80%放射肿瘤科医生报告当前证据表明立体定向体部放疗对可手术Ⅰ期非小细胞肺癌患者的获益与手术相同或更好,28%非放射肿瘤科医生持相同观点(P < .01)。
  • 94%放射肿瘤科医生 versus 62%非放射肿瘤科医生允许可手术患者入组立体定向体部放疗对比手术的随机对照试验(P < .01)。
  • 82%放射肿瘤科医生和87%非放射肿瘤科医生认为即使随机对照试验显示立体定向体部放疗生存更好,改变胸外科实践也有些困难、非常困难或不可能(P = .066)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The current standard of care for surgically eligible stage I non-small cell lung cancer (NSCLC) is surgical resection, but emerging data suggest that stereotactic body radiation therapy (SBRT) is potentially as effective as surgery. However, specialist views of the current evidence about SBRT and how they would incorporate a randomized controlled trial (RCT) into practice is unclear. We sought to understand specialist opinions about evidence regarding treatment of stage I NSCLC and how this translates into practice and clinical trial implementation. METHODS AND MATERIALS: We used a 28-item, web-based survey that invited all participating providers from the American Society for Radiation Oncology, American Thoracic Society Thoracic Oncology Assembly, and the International Association for the Study of Lung Cancer to share opinions regarding practice beliefs, treatment of stage I NSCLC, and a clinical trial scenario. RESULTS: A total of 959 surveys were completed; 64% were from radiation oncologists (ROs) and 49% were from outside the United States. The majority of ROs (80%) reported that current evidence indicates that SBRT has the same or a better benefit compared with surgery for surgically eligible patients with stage I NSCLC; 28% of non-radiation oncologists (NROs) indicated the same (P < .01). Almost all ROs (94%), compared with 62% of NROs, would permit surgically eligible patients to enroll in an RCT of SBRT versus surgery (P < .01). Most ROs (82%) and NROs (87%) believed that changing practice in thoracic surgery would be somewhat difficult, very difficult, or impossible (P = .066) even if an RCT showed better survival with SBRT. CONCLUSIONS: NROs believe that SBRT is much less effective than surgery, contrary to ROs, who believe that they are similar. Most would support an RCT, but NROs would do so less. Changes in surgical practice may be challenging even if an RCT shows better mortality and quality of life with SBRT. These results are helpful in the creation and dissemination of RCTs that are designed to understand this question.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lammers A, Mitin T, Moghanaki D, et al. Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey. Adv Radiat Oncol. 2018. PMID: 29904736. doi:10.1016/j.adro.2018.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。